279 related articles for article (PubMed ID: 29550629)
21. Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease.
Richet C; Huynh A; Dimeglio C; Borel C; Lepage B; Boulinguez S; Marguery MC; Paul C; Bulai Livideanu C
Dermatology; 2018; 234(1-2):23-30. PubMed ID: 29788024
[TBL] [Abstract][Full Text] [Related]
22. Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: Prospective single-center study.
Sakellari I; Gavriilaki E; Batsis I; Mallouri D; Panteliadou AK; Lazaridou A; Vardi A; Constantinou V; Yannaki E; Papalexandri A; Kaloyannidis P; Smias C; Anagnostopoulos A
J Clin Apher; 2018 Dec; 33(6):654-660. PubMed ID: 30394564
[TBL] [Abstract][Full Text] [Related]
23. Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients.
Gagliardi TA; Milner J; Cairo MS; Steinberg A
Cureus; 2022 Sep; 14(9):e29195. PubMed ID: 36258935
[TBL] [Abstract][Full Text] [Related]
24. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
[TBL] [Abstract][Full Text] [Related]
25. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
Yao G; Albon E; Adi Y; Milford D; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2006 Dec; 10(49):iii-iv, ix-xi, 1-157. PubMed ID: 17134597
[TBL] [Abstract][Full Text] [Related]
26. Continuation of systemic treatments and outcomes for patients with chronic graft-versus-host disease in the USA.
Huang X; Joshi N; Luo L; Shamseddine N; Gao X
Immunotherapy; 2021 Apr; 13(5):387-395. PubMed ID: 33504204
[No Abstract] [Full Text] [Related]
27. Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: results of treatment with the COBE Spectra System.
Hautmann AH; Wolff D; Hahn J; Edinger M; Schirmer N; Ammer J; Holler B; Landfried K; Hautmann MG; Ahrens N; Ugocsai P; Andreesen R; Holler E
Bone Marrow Transplant; 2013 Mar; 48(3):439-45. PubMed ID: 22922407
[TBL] [Abstract][Full Text] [Related]
28. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
29. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
[TBL] [Abstract][Full Text] [Related]
30. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
31. Novel Pharmacological Treatment Options of Steroid-Refractory Graft-versus-Host Disease.
Kovalenko I; Saleem T; Shah M; Seyedroudbari S; Golubykh K; Ali R; Mirza T; Laek B; Wahab A; Chattaraj A; Proskuriakova E; Garg C; Khan R
Adv Hematol; 2023; 2023():9949961. PubMed ID: 38094101
[TBL] [Abstract][Full Text] [Related]
32. Extracorporeal photopheresis as first-line strategy in the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: A single-center experience.
Sestili S; Eder S; Belhocine R; Dulery R; Battipaglia G; Brissot E; Mediavilla C; Banet A; van de Wyngaert Z; Paviglianiti A; Ledraa T; Bonin A; Mohty M; Malard F
Cytotherapy; 2020 Aug; 22(8):445-449. PubMed ID: 32434750
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal follow-up of response status and concomitant immunosuppression in patients treated with extracorporeal photopheresis for chronic graft versus host disease.
Nygaard M; Karlsmark T; Andersen NS; Schjødt IM; Petersen SL; Friis LS; Kornblit BT; Sengeløv H
Bone Marrow Transplant; 2019 Jan; 54(1):35-43. PubMed ID: 29740177
[TBL] [Abstract][Full Text] [Related]
34. Steroid-sparing effect of extracorporeal photopheresis in the therapy of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Ussowicz M; Musiał J; Mielcarek M; Tomaszewska A; Nasiłowska-Adamska B; Kałwak K; Gorczyńska E; Mariańska B; Chybicka A
Transplant Proc; 2013 Nov; 45(9):3375-80. PubMed ID: 24182819
[TBL] [Abstract][Full Text] [Related]
35. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
36. Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects.
Wang L; Ni M; Hückelhoven-Krauss A; Sellner L; Hoffmann JM; Neuber B; Luft T; Hegenbart U; Schönland S; Kleist C; Sill M; Chen BA; Wuchter P; Eckstein V; Krüger W; Hilgendorf I; Yerushalmi R; Nagler A; Müller-Tidow C; Ho AD; Dreger P; Schmitt M; Schmitt A
Front Immunol; 2018; 9():2207. PubMed ID: 30349527
[TBL] [Abstract][Full Text] [Related]
37. First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate.
Wang Y; Xu LP; Liu DH; Chen H; Chen YH; Han W; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2009 Apr; 15(4):505-11. PubMed ID: 19285639
[TBL] [Abstract][Full Text] [Related]
38. Total nodal irradiation in patients with severe treatment-refractory chronic graft-versus-host disease after allogeneic stem cell transplantation: Response rates and immunomodulatory effects.
Hautmann AH; Wolff D; Hilgendorf I; Fehn U; Edinger M; Hoffmann P; Herr W; Kölbl O; Holler B; Sporrer D; Holler E; Hautmann MG
Radiother Oncol; 2015 Aug; 116(2):287-93. PubMed ID: 26255761
[TBL] [Abstract][Full Text] [Related]
39. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors.
Foss FM; DiVenuti GM; Chin K; Sprague K; Grodman H; Klein A; Chan G; Stiffler K; Miller KB
Bone Marrow Transplant; 2005 Jun; 35(12):1187-93. PubMed ID: 15852025
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Nassar A; Elgohary G; Elhassan T; Nurgat Z; Mohamed SY; Aljurf M
J Transplant; 2014; 2014():980301. PubMed ID: 25405023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
